Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Long-term effectiveness of glatiramer acetate in clinical practice conditions.
Cervical cord and ventricle affection in neuromyelitis optica.
Reassessing the risk of natalizumab-associated PML.
Associations Between Fatigue and Disability, Functional Mobility, Depression, and Quality of Life in People with Multiple Sclerosis.
PML in a patient treated with dimethyl fumarate from a compounding pharmacy.
The Correlation between the Virus- and Brain Antigen-Specific B Cell Response in the Blood of Patients with Multiple Sclerosis.
Measuring participation as defined by the World Health Organization in the International Classification of Functioning, Disability and Health. Psychometric properties of the Ghent Participation Scale.
Regulation of B cell function by the immunosuppressive agent leflunomide.
Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
Women's Issues in Multiple Sclerosis.
The possible effects of the solar and geomagnetic activity on multiple sclerosis.
Dimethyl fumarate attenuates cerebral edema formation by protecting the blood-brain barrier integrity.
An inhibitor of chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination.
CLIC1 regulates dendritic cell antigen processing and presentation by modulating phagosome acidification and proteolysis.
FDA approves Genzyme’s AUBAGIO® (teriflunomide), a once-daily, oral treatment for relapsing multiple sclerosis
Mechanism of action for leflunomide in rheumatoid arthritis.
Susceptibility tensor imaging (STI) of the brain.
[Reduction of spastic increased muscle tone in multiple sclerosis by the nonopioid analgesic flupirtine].
ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Multiple sclerosis review.
Episode 6 with Dr. Jeffrey Dunn on biomarkers and personalized medicine
Hyperforin-loaded gold nanoparticle alleviates experimental autoimmune encephalomyelitis by suppressing Th1 and Th17 cells and upregulating regulatory T cells.
Detailed results from Biogen Idec and AbbVie's pivotal Phase 3 DECIDE study further define the efficacy and safety profile of ZINBRYTA™ (daclizumab high-yield process)
Extended interval dosing of natalizumab in multiple sclerosis.
Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis.

Pages